FiberSense AG announces that its Continuous Glucose Monitoring (CGM) system has obtained the CE mark, a regulatory milestone that enables the company to proceed with preparations for commercial launch. The announcement from multiple outlets describes the CE marking as a key step toward commercialization of the CGM product. Sources also note that the CE mark represents the first phase of FiberSense’s broader strategy involving continuous sensing of additional biomarkers beyond glucose, referred to as a move toward a wider “CxM” biomarker monitoring approach. The coverage does not provide additional clinical details, performance results, or information about distribution timelines, pricing, or specific initial markets. All reporting is consistent that the company is using the regulatory approval as a basis to advance launch activities. The announcements are dated June 17, 2026, and issued from Basel, Switzerland, by FiberSense AG, with the company framing the CE mark as paving the way for the start of commercial availability of its CGM system while laying groundwork for future multi-marker monitoring.